公司新闻 | 标新生物获得临港新片区2024年度高新产业和科技创新专项项目立项
发布日期：2024-06-04 文章来源：标新生物
近日，临港新片区管委会高新产业和科技创新处发布了《中国（上海）自由贸易试验区临港新片区管理委员会关于公示2024年度第一批高新产业和科技创新专项项目立项的通知》。根据第三方评估机构评审结果，经临港新片区管委会专题会议审议，标新生物申报的关键核心技术研发项目“I类新药GT919用于恶性血液肿瘤治疗的开发”立项通过，将获得管委会的配套资助。
本批专项项目是临港管委会高科处根据《中国（上海）自由贸易试验区临港新片区专项发展资金预算管理办法》（沪财预〔2023〕118号）、《中国（上海）自由贸易试验区临港新片区促进前沿重点产业高质量发展若干政策》（沪自贸临管经〔2023〕193号），为实现前沿产业产业链供应链自主安全可控，支持发展重点产业中填补国内空白、实现国产替代的产品研发，对关键核心技术和颠覆性技术有效突破给予的特别支持。新片区共25个项目获得立项。
此次临港新片区管委会的专项资金支持，对标新生物而言是一股强大的推动力。这不仅显现出临港新片区管委会相关部门对科技创新的深切关注与高度重视，更为标新生物的发展提供了坚实的保障。作为一家专注于蛋白降解技术、处于临床阶段的创新生物医药科技企业，标新生物始终致力于技术的突破和产品的转化，深感使命重大。在此过程中，我们深切明白，创新企业的成长离不开各级政府部门的引导和支持，管委会在科技创新领域的政策扶持，为我们营造了良好的创新环境，提供了宝贵的发展机遇。
下一步，标新生物将以此为契机，充分发挥创新企业优势作用，继续加大创新药研发投入、培养高技术人才队伍、不断注入技术创新的新动能，努力提升企业核心竞争力，以前瞻的眼光、严谨的科学态度，把握生物医药变革发展带来的无限可能，持续推动蛋白降解剂药物研发创新走深走实，为增进民众健康福祉和构建健康中国贡献力量。
Recently, the High-tech Department of the Lin-gang Special Area Administration released the Notice of China (Shanghai) Pilot Free Trade Zone Lin-gang Special Area Administration on the Publication of the First Batch of High-tech Special Projects in the Year of 2024. According to the evaluation results of the third-party evaluator and the consideration of the special meeting of the Lin-gang Special Area Administration, the project of Key Core Technology R&D Project “Development of Class I New Drug GT919 for the Treatment of hematological malignancies” declared by Gluetacs has been approved, and it will be awarded the matching funding by the Administration.
This batch of special projects is the special support given by the High-tech Department of the Lin-gang Special Area Administration according to the relevant policies, in order to realize the independency, security and control of the supply chain of the frontier industry chain, to support the development of key industries to fill the gaps in the domestic market, to realize the research and development of domestically produced substitutes, and to give special support to the effective breakthroughs in the key core technologies and transformative technologies. A total of 25 projects in the Special Area won.
The special financial support from the Lin-gang Special Area Administrationis a strong driving force for Gluetacs. It not only shows the deep concern and great attention of the relevant departments of Lin-gang Special Area Administration on science and technology innovation, but also provides a solid guarantee for the development of Gluetacs. As an innovative clinical-stage biopharmaceutical technology enterprise specializing in protein degradation technology, Gluetacs has always been committed to technological breakthroughs and scientific research achievement transformation, with deeply aware of the significance of its mission. We deeply understand that the growth of innovative enterprises cannot be separated from the guidance and support of government departments at all levels, and the policy support of the Administration in the field of science and technology innovation has created a favorable innovation environment and provided us with valuable development opportunities.
In the next step, Gluetacs will take this opportunity to give full play to the advantages of innovative enterprises, continue to increase investment in R&D of innovative drugs, cultivate a team of high-tech talents, continuously foster new growth drivers of technological innovation, strive to enhance the core capabilities of enterprises, grasp the infinite possibilities brought by the revolution in the field of medicine, and continue to promote the R&D innovation of protein degraders in a deeper and more practical way to contribute to the enhancement of the people’s health and well-being and the construction of a healthy China.